A qualitative study to explore the symptoms and impacts of Crohn's disease and to develop the Crohn's Disease Diary.

Content validity Crohn’s disease Instrument development Patient-reported outcomes Symptoms

Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Jan 2023
Historique:
accepted: 06 08 2022
pubmed: 3 9 2022
medline: 12 1 2023
entrez: 2 9 2022
Statut: ppublish

Résumé

To explore symptoms and disease impacts of Crohn's disease and to develop a new patient-reported outcomes (PRO) measure according to industry best practices. A conceptual model of relevant symptoms experienced by patients with Crohn's disease was developed following a literature review. Three rounds of combined qualitative semi-structured concept elicitation and cognitive debriefing interviews with 36 patients (≥ 16 years) with Crohn's disease and 4 clinicians were conducted to further explore the most commonly reported and most bothersome symptoms to patients. Interview results were used to update the conceptual model as well as items and response options included in The Crohn's Disease Diary, a new PRO measure. All patients (N = 36) reported abdominal pain, loose or liquid bowel movements, and high or increased frequency of bowel movements, with most reporting these symptoms spontaneously (100%, 92%, and 75%, respectively). All patients reported bowel movement urgency, but 61% reported this symptom only when probed. Most also reported that symptoms impacted activities of daily living, work/school, and emotional, social, and physical functioning (overall, 78%-100%; spontaneously, 79% - 92%). Data regarding core symptoms of Crohn's disease from clinician concept elicitation interviews supported patient data. The 17-item Crohn's Disease Diary assesses core symptoms and impacts of Crohn's disease over 24 h, and extraintestinal manifestations over 7 days. The content validity of the diary was confirmed during cognitive debriefing interviews. The Crohn's Disease Diary is a new PRO measure for the assessment of Crohn's disease symptoms and impacts, developed according to industry best practices.

Identifiants

pubmed: 36056191
doi: 10.1007/s11136-022-03233-9
pii: 10.1007/s11136-022-03233-9
pmc: PMC9829647
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

209-223

Informations de copyright

© 2022. The Author(s).

Références

Biomed Pharmacother. 2000 Aug;54(7):388-93
pubmed: 10989978
J Patient Rep Outcomes. 2017;2(1):24
pubmed: 29770803
Clin Gastroenterol Hepatol. 2020 Jan;18(1):14-23
pubmed: 31301452
Gastroenterology. 1989 Mar;96(3):804-10
pubmed: 2644154
Digestion. 2007;76(2):141-8
pubmed: 18239406
Nurse Educ Today. 2017 Sep;56:29-34
pubmed: 28651100
Aliment Pharmacol Ther. 2015 Jan;41(1):77-86
pubmed: 25348809
Gastroenterology. 2004 May;126(6):1518-32
pubmed: 15168364
Nat Rev Dis Primers. 2020 Apr 2;6(1):22
pubmed: 32242028
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508
J Crohns Colitis. 2015 Aug;9(8):601-6
pubmed: 25908718
Turk J Gastroenterol. 2019 Jan;30(1):33-39
pubmed: 30644362
Psychol Health. 2010 Dec;25(10):1229-45
pubmed: 20204937
Gastroenterology. 1976 Mar;70(3):439-44
pubmed: 1248701
World J Gastroenterol. 2008 Jul 14;14(26):4127-30
pubmed: 18636655
Value Health. 2011 Dec;14(8):967-77
pubmed: 22152165

Auteurs

Rebecca Williams-Hall (R)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK.

Claire Trennery (C)

Value Evidence Outcomes, GlaxoSmithKline, Brentford, London, UK. claire.l.trennery@gsk.com.

Kate Sully (K)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK.

Samantha Wratten (S)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK.

Anya Francis (A)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK.

Dale Chandler (D)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK.

Jessica Flynn (J)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK.

Megan Turner (M)

Value Evidence Outcomes, GlaxoSmithKline, Collegeville, PA, USA.

Daniel J B Marks (DJB)

Discovery Medicine, GlaxoSmithKline, Stevenage, Hertfordshire, UK.

Alfred Sackeyfio (A)

Value Evidence Outcomes, GlaxoSmithKline, Brentford, London, UK.

Marguerite Bracher (M)

Value Evidence Outcomes, GlaxoSmithKline, Stevenage, Hertfordshire, UK.

Alex Walker (A)

Clinical Sciences, GlaxoSmithKline, Brentford, London, UK.

Louise Walker-Nthenda (L)

Value Evidence Outcomes, GlaxoSmithKline, Stevenage, Hertfordshire, UK.

Rob Arbuckle (R)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, UK.

Tom Keeley (T)

Value Evidence Outcomes, GlaxoSmithKline, Brentford, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH